FEASIBILITY OF BORON NEUTRON CAPTURE THERAPY USING PARTICLE ACCELERATOR

核工业工人的中子照射，测井工人， 和航空公司机组人员，包括大剂量的中子 能量低于100千电子伏特。此外，正常组织剂量来自 硼中子俘获疗法将主要来自低能量 中子。微剂量学理论预测相对剂量减少 能量以下的中子的生物有效性(RBE) 350keV与高能中子相比，这是因为 低能中子与生物材料的相互作用 在既有Let值减小(停止)的组织中反冲质子 功率)和减小的范围。基于这些考虑，以及 有限的生物数据，目前分配的辐射权重 能量来自的中子的因子(以前的品质因子) 10keV到100keV比高能中子要小。通过 相比之下，一些报告表明， 24keV中子与快中子相似。两个单元格 确定肿瘤的存活率和致癌转化诱导。 C3H10T1/2细胞受两束低能中子束照射 剂量平均为40和70keV的平均能量，并与 更高能量的中子和X射线。结果与实验结果一致 目前建议降低的低能中子数值 辐射加权系数，与快中子相比。

Neutron exposure of workers in the nuclear industry, well loggers, and airline crew members, includes significant doses of neutrons with energies below 100 keV. In addition, the normal tissue dose from boron neutron capture therapy will largely be from low-energy neutrons. Microdosimetric theory predicts decreasing relative biological effectiveness (RBE) for neutrons with energies below about 350 keV compared to that for higher energy neutrons; this is because interactions of low-energy neutrons with biological material give rise to recoil protons in tissue that have both decreasing LET (stopping power), and decreasing range. Based on such considerations, and limited biological data, the currently assigned radiation weighting factor (previously the quality factor) for neutrons with energies from 10 keV to 100 keV is less than that for higher-energy neutrons. By contrast, a few reports have suggested that the biological effects of 24 keV neutrons is similar to that of fast neutrons. Both cell survival and oncogenic transformation induction were determined for C3H10T1/2 cells exposed to two low-energy neutron beams with dose-averaged mean energies of 40 and 70 keV, and compared to that for higher energy neutrons and X rays. The results were consistent with the currently recommended decreased values for low-energy neutron radiation weighting factors, compared to fast neutrons.